Shanghai Junshi Biosciences Aktie [WKN DE: A2N9PC / ISIN: CNE100003FF7]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Shanghai Junshi Biosciences Co., Ltd Registered Shs -H- Unitary Reg S-144A

16.11.24		Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab (GlobeNewswire)
15.10.24		Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR (GlobeNewswire)
25.09.24		Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab (GlobeNewswire)
31.08.24		Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates (GlobeNewswire)
12.08.24		Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma (GlobeNewswire)
26.07.24		Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab (GlobeNewswire)
18.07.24		Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma (GlobeNewswire)
25.06.24		Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC (GlobeNewswire)
18.06.24		Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer (GlobeNewswire)
12.06.24		Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint (GlobeNewswire)
25.04.24		Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab (GlobeNewswire)
07.04.24		Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer (GlobeNewswire)
29.03.24		Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates (GlobeNewswire)
02.02.24		Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority (GlobeNewswire)
18.01.24		Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cance (GlobeNewswire)
10.01.24		Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medi (GlobeNewswire)
02.01.24		Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients (GlobeNewswire)
02.12.23		Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA (GlobeNewswire)
23.11.23		Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19 (GlobeNewswire)
27.10.23		Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 (GlobeNewswire)
31.08.23		Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates (GlobeNewswire)
20.07.23		Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer (GlobeNewswire)
12.07.23		Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab (GlobeNewswire)
29.06.23		Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer (GlobeNewswire)
23.05.23		Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer (GlobeNewswire)
07.05.23		Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries (GlobeNewswire)
27.04.23		Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma (GlobeNewswire)
20.04.23		Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung (GlobeNewswire)
12.04.23		Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint (GlobeNewswire)
12.04.23		Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients (GlobeNewswire)
31.03.23		Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates (GlobeNewswire)
29.03.23		Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia (GlobeNewswire)
28.02.23		Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies (GlobeNewswire)
21.02.23		Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study (GlobeNewswire)
15.02.23		Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal C (GlobeNewswire)
24.11.22		Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency (GlobeNewswire)
22.11.22		Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection (GlobeNewswire)
15.11.22		Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab (GlobeNewswire)
12.10.22		Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non (GlobeNewswire)
20.09.22		Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer (GlobeNewswire)
31.08.22		Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates (GlobeNewswire)
26.08.22		Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) (GlobeNewswire)
18.08.22		Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection (GlobeNewswire)
21.07.22		Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
06.07.22		Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
07.06.22		Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022 (GlobeNewswire)
25.05.22		VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint (GlobeNewswire)
16.05.22		Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcin (GlobeNewswire)
02.05.22		Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA (GlobeNewswire)
14.04.22		Junshi Biosciences and Coherus Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States (GlobeNewswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.11.2024 16:26
Kaufwert:	EUR
	Hinzufügen Speichern